doi:10.1210/endo.141.11.7873
Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available
Preclinical studies show no significant toxicity at therapeutic doses, with treated animals displaying no adverse behavioral changes or organ dysfunction
Vitamin B12 is key for the brain, healthy blood cells, and DNA
Final Thoughts on AOD-9604s Benefits AOD-9604 is an exciting fat-burning peptide with the potential for targeted fat loss, metabolic benefits, and joint repair
It is normally involved in the metabolism of every cell of the body, especially affecting DNA synthesis and regulation, but also fatty acids synthesis and energy production